<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>PLAQUENIL- hydroxychloroquine sulfate tablet, film coated </strong><br>sanofi-aventis U.S. LLC<br></p></div>
<h1>PLAQUENIL®<br>HYDROXYCHLOROQUINE SULFATE, USP</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="section-1"></a><p></p>
<h1>WARNING</h1>
<p class="First">PHYSICIANS SHOULD COMPLETELY FAMILIARIZE THEMSELVES WITH THE COMPLETE CONTENTS OF THIS LEAFLET BEFORE PRESCRIBING HYDROXYCHLOROQUINE.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-1"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Hydroxychloroquine sulfate is a colorless crystalline solid, soluble in water to at least 20 percent; chemically the drug is 2-[[4-[(7-Chloro-4-quinolyl)amino]pentyl]ethylamino] ethanol sulfate (1:1). </p>
<p>PLAQUENIL (hydroxychloroquine sulfate) tablets contain 200 mg hydroxychloroquine sulfate, equivalent to 155 mg base, and are for oral administration.</p>
<p><span class="Italics">Inactive Ingredients:</span> Dibasic Calcium Phosphate, Hydroxypropyl Methylcellulose, Magnesium Stearate, Polyethylene glycol 400, Polysorbate 80, Corn Starch, Titanium Dioxide.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2"></a><p></p>
<h1>ACTIONS</h1>
<p class="First">The drug possesses antimalarial actions and also exerts a beneficial effect in <span class="product-label-link" type="condition" conceptid="255891" conceptname="Lupus erythematosus">lupus erythematosus</span> (chronic discoid or systemic) and acute or chronic <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span>. The precise mechanism of action is not known.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-3"></a><p></p>
<h1>INDICATIONS</h1>
<p class="First">PLAQUENIL is indicated for the suppressive treatment and treatment of acute attacks of <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span> due to <span class="Italics">Plasmodium vivax</span>, <span class="Italics">P. malariae</span>, <span class="Italics">P. ovale</span>, and susceptible <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">P. falciparum</span>. It is also indicated for the treatment of discoid and <span class="product-label-link" type="condition" conceptid="257628" conceptname="Systemic lupus erythematosus">systemic lupus erythematosus</span>, and <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span>.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-4"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Use of this drug is contraindicated (1) in the presence of retinal or visual field changes attributable to any 4-aminoquinoline compound, (2) in patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to 4-aminoquinoline compounds, and (3) for long-term therapy in children.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="section-5"></a><p></p>
<h1>WARNINGS, General</h1>
<p class="First">PLAQUENIL is not effective against chloroquine-resistant <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">P. falciparum</span>.</p>
<p><span class="Bold">Before starting a long-term treatment, both eyes should be carefully examined for visual acuity, central visual field and color vision. Examination should also include fundoscopy. These examinations should be repeated at least annually. Retinal toxicity is largely dose-related</span>.</p>
<p>The risk of <span class="product-label-link" type="condition" conceptid="4188175" conceptname="Retinal damage">retinal damage</span> is small with daily doses of up to 6.5 mg/kg body weight. Exceeding the recommended daily dose sharply increases the risk of retinal toxicity. This examination should be more frequent and adapted to the patient in the following situations:</p>
<dl>
<dt>-</dt>
<dd>daily dosage exceeding 6.5 mg/kg ideal body weight. Absolute body weight used as a guide to dosage, could result in an overdosage in the obese;</dd>
<dt>-</dt>
<dd><span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span>;</dd>
<dt>-</dt>
<dd>cumulative dose more than 200 g;</dd>
<dt>-</dt>
<dd>elderly;</dd>
<dt>-</dt>
<dd>impaired visual acuity. </dd>
</dl>
<p>If any <span class="product-label-link" type="condition" conceptid="374034" conceptname="Visual disturbance">visual disturbance</span> occurs (visual acuity, color vision), the drug should be immediately discontinued and the patient closely observed for possible progression of the abnormality. Retinal changes (and <span class="product-label-link" type="condition" conceptid="374034" conceptname="Visual disturbance">visual disturbances</span>) may progress even after cessation of the therapy. (See <a href="#Adverse">ADVERSE REACTIONS</a> section)</p>
<p><span class="product-label-link" type="condition" conceptid="4322252" conceptname="Suicidal behavior">Suicidal behavior</span> has been reported in very rare cases in patients treated with hydroxychloroquine.</p>
<p>Children are especially sensitive to the 4-aminoquinoline compounds. A number of fatalities have been reported following the accidental ingestion of chloroquine, sometimes in relatively small doses (0.75 g or 1 g in one 3-year-old child). Patients should be strongly warned to keep these drugs out of the reach of children.</p>
<p>Use of PLAQUENIL in patients with <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">psoriasis</span> may precipitate a severe attack of <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">psoriasis</span>. When used in patients with <span class="product-label-link" type="condition" conceptid="4305376" conceptname="Porphyria">porphyria</span> the condition may be exacerbated. The preparation should not be used in these conditions unless in the judgment of the physician the benefit to the patient outweighs the possible hazard.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.1"></a><p></p>
<h2>Usage in Pregnancy</h2>
<p class="First">Usage of this drug during pregnancy should be avoided except in the suppression or treatment of <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span> when in the judgment of the physician the benefit outweighs the possible hazard. It should be noted that radioactively-tagged chloroquine administered intravenously to pregnant, pigmented CBA mice passed rapidly across the placenta. It accumulated selectively in the melanin structures of the fetal eyes and was retained in the ocular tissues for five months after the drug had been eliminated from the rest of the body.</p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="section-6"></a><p></p>
<h1>PRECAUTIONS, General</h1>
<p class="First">Antimalarial compounds should be used with caution in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic disease</span> or <span class="product-label-link" type="condition" conceptid="4218106" conceptname="Alcoholism">alcoholism</span> or in conjunction with known hepatotoxic drugs.</p>
<p>Periodic blood cell counts should be made if patients are given prolonged therapy. If any severe <span class="product-label-link" type="condition" conceptid="40528016" conceptname="Disorder of hematopoietic system">blood disorder</span> appears which is not attributable to the disease under treatment, discontinuation of the drug should be considered. The drug should be administered with caution in patients having G-6-PD (glucose-6-phosphate dehydrogenase) deficiency.</p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="Adverse"></a><a name="section-7"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First"><span class="Bold Italics">Psychiatric disorders:</span> <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">Nervousness</span>, <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">emotional lability</span>, <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span>, <span class="product-label-link" type="condition" conceptid="4322252" conceptname="Suicidal behavior">suicidal behavior</span>.</p>
<p><span class="Bold Italics"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous system disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span> have been reported with this class of drugs.</p>
<p><span class="Bold Italics"><span class="product-label-link" type="condition" conceptid="375252" conceptname="Disorder of eye">Eye disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="376103" conceptname="Retinopathy">Retinopathy</span> with changes in <span class="product-label-link" type="condition" conceptid="4083855" conceptname="Abnormal pigment">pigmentation</span> and <span class="product-label-link" type="condition" conceptid="377286" conceptname="Visual field defect">visual field defects</span> have been reported. In its early form, it appears reversible on discontinuation of hydroxychloroquine. If allowed to develop, there may be a risk of progression even after treatment withdrawal. Cases of maculopathies and <span class="product-label-link" type="condition" conceptid="4083487" conceptname="Macular drusen">macular degeneration</span> have been reported and may be irreversible.</p>
<p><span class="Bold Italics">Skin and subcutaneous tissue disorders:</span> <span class="product-label-link" type="condition" conceptid="4032934" conceptname="Vesiculobullous rash">Bullous eruptions</span> including very rare cases of <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">Erythema multiforme</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>, <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity</span> and <span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">exfoliative dermatitis</span> have been reported.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-8"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">The 4-aminoquinoline compounds are very rapidly and completely absorbed after ingestion, and in accidental overdosage, or rarely with lower doses in hypersensitive patients, toxic symptoms may occur within 30 minutes. The symptoms of overdosage may include <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, <span class="product-label-link" type="condition" conceptid="374034" conceptname="Visual disturbance">visual disturbances</span>, <span class="product-label-link" type="condition" conceptid="443240" conceptname="Collapse">cardiovascular collapse</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>, <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>, rhythm and conduction disorders including QT prolongation, torsade de pointe, <span class="product-label-link" type="condition" conceptid="4103295" conceptname="Ventricular tachycardia">ventricular tachycardia</span> and <span class="product-label-link" type="condition" conceptid="437894" conceptname="Ventricular fibrillation">ventricular fibrillation</span>, followed by sudden potentially fatal respiratory and <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span>. Immediate medical attention is required, as these effects may appear shortly after the <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>.  Treatment is symptomatic and must be prompt with immediate evacuation of the stomach by <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span> (at home, before transportation to the hospital) or gastric lavage until the stomach is completely emptied.  If finely powdered, activated charcoal is introduced by the stomach tube, after lavage, and within 30 minutes after ingestion of the tablets, it may inhibit further intestinal absorption of the drug.  To be effective, the dose of activated charcoal should be at least five times the estimated dose of hydroxychloroquine ingested.  <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Convulsions</span>, if present, should be controlled before attempting gastric lavage.  If due to cerebral stimulation, cautious administration of an ultrashort-acting barbiturate may be tried but, if due to <span class="product-label-link" type="condition" conceptid="313601" conceptname="Oxygen supply absent">anoxia</span>, it should be corrected by oxygen administration, artificial respiration or, in <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span> with <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, by vasopressor therapy.  Because of the importance of supporting respiration, tracheal intubation or tracheostomy, followed by gastric lavage, may also be necessary.  Exchange transfusions have been used to reduce the level of 4-aminoquinoline drug in the blood.</p>
<p>A patient who survives the acute phase and is asymptomatic should be closely observed for at least six hours.  Fluids may be forced, and sufficient ammonium chloride (8 g daily in divided doses for adults) may be administered for a few days to acidify the urine to help promote urinary excretion in cases of both overdosage and sensitivity.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9"></a><p></p>
<h1><span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">MALARIA</span></h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.1"></a><p></p>
<h2>Actions</h2>
<p class="First">Like chloroquine phosphate, USP, PLAQUENIL is highly active against the erythrocytic forms of <span class="Italics">P. vivax</span> and <span class="Italics">P. malariae</span> and most <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">P. falciparum</span> (but not the gametocytes of <span class="Italics">P. falciparum</span>).</p>
<p>PLAQUENIL does not prevent relapses in patients with <span class="Italics">P. vivax</span> or <span class="Italics">P. malariae</span> <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span> because it is not effective against exo-erythrocytic forms of the parasite, nor will it prevent <span class="Italics">P. vivax</span> or <span class="Italics">P. malariae</span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> when administered as a <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span>. It is highly effective as a suppressive agent in patients with <span class="Italics">P. vivax</span> or <span class="Italics">P. malariae</span> <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span>, in terminating acute attacks, and significantly lengthening the interval between treatment and relapse. In patients with <span class="Italics">P. falciparum</span> <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span>, it abolishes the acute attack and effects complete cure of the <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, unless due to a resistant <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span> of <span class="Italics">P. falciparum</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.2"></a><p></p>
<h2>Indications</h2>
<p class="First">PLAQUENIL is indicated for the treatment of acute attacks and suppression of <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.3"></a><p></p>
<h2>Warnings</h2>
<p class="First">In recent years, it has been found that certain <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">P. falciparum</span> have become resistant to 4-aminoquinoline compounds (including hydroxychloroquine) as shown by the fact that normally adequate doses have failed to prevent or cure clinical <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span> or parasitemia. Treatment with quinine or other specific forms of therapy is therefore advised for patients infected with a resistant <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span> of parasites.</p>
<p><span class="Bold">Before starting a long-term treatment, both eyes should be carefully examined for visual acuity, central visual field and color vision. Examination should also include fundoscopy. These examinations should be repeated at least annually. Retinal toxicity is largely dose-related</span>.</p>
<p>The risk of <span class="product-label-link" type="condition" conceptid="4188175" conceptname="Retinal damage">retinal damages</span> is small with daily doses of up to 6.5 mg/kg body weight. Exceeding the recommended daily dose sharply increases the risk of retinal toxicity. This examination should be more frequent and adapted to the patient in the following situations:</p>
<dl>
<dt>-</dt>
<dd>daily dosage exceeding 6.5 mg/kg ideal body weight. Absolute body weight used as a guide to dosage, could result in an overdosage in the obese;</dd>
<dt>-</dt>
<dd><span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span>;</dd>
<dt>-</dt>
<dd>cumulative dose more than 200 g;</dd>
<dt>-</dt>
<dd>elderly;</dd>
<dt>-</dt>
<dd>impaired visual acuity. </dd>
</dl>
<p>If any <span class="product-label-link" type="condition" conceptid="374034" conceptname="Visual disturbance">visual disturbance</span> occurs (visual acuity, color vision), the drug should be immediately discontinued and the patient closely observed for possible progression of the abnormality. Retinal changes (and <span class="product-label-link" type="condition" conceptid="374034" conceptname="Visual disturbance">visual disturbances</span>) may progress even after cessation of the therapy. (See <a href="#Adverse">ADVERSE REACTIONS</a>)</p>
<p><span class="product-label-link" type="condition" conceptid="4322252" conceptname="Suicidal behavior">Suicidal behavior</span> has been reported in very rare cases in patients treated with hydroxychloroquine.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.4"></a><p></p>
<h2>Adverse Reactions</h2>
<p class="First">Following the administration in doses adequate for the treatment of an acute malarial attack, mild and transient <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, and gastrointestinal complaints (<span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal cramps</span> and, on rare occasions, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>) may occur. <span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">Cardiomyopathy</span> has been rarely reported with high daily dosages of hydroxychloroquine.</p>
<p><span class="Bold Italics">Psychiatric disorders:</span> <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">Nervousness</span>, <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">emotional lability</span>, <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span>, <span class="product-label-link" type="condition" conceptid="4322252" conceptname="Suicidal behavior">suicidal behavior</span>.</p>
<p><span class="Bold Italics"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous system disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span> have been reported with this class of drugs.</p>
<p><span class="Bold Italics"><span class="product-label-link" type="condition" conceptid="375252" conceptname="Disorder of eye">Eye disorders</span></span><span class="Italics">:</span> <span class="product-label-link" type="condition" conceptid="376103" conceptname="Retinopathy">Retinopathy</span> with changes in <span class="product-label-link" type="condition" conceptid="4083855" conceptname="Abnormal pigment">pigmentation</span> and <span class="product-label-link" type="condition" conceptid="377286" conceptname="Visual field defect">visual field defects</span> have been reported. In its early form, it appears reversible on discontinuation of hydroxychloroquine. If allowed to develop, there may be a risk of progression even after treatment withdrawal. Cases of maculopathies and <span class="product-label-link" type="condition" conceptid="4083487" conceptname="Macular drusen">macular degeneration</span> have been reported and may be irreversible. </p>
<p><span class="Bold Italics">Skin and subcutaneous tissue disorders:</span> <span class="product-label-link" type="condition" conceptid="4032934" conceptname="Vesiculobullous rash">Bullous eruptions</span> including very rare cases of <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">Erythema multiforme</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>, <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity</span> and <span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">exfoliative dermatitis</span> have been reported.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.5"></a><p></p>
<h2>Dosage and Administration</h2>
<p class="First">One tablet of 200 mg of hydroxychloroquine sulfate is equivalent to 155 mg base.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.5.1"></a><p></p>
<h3></h3>
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">Malaria</span></span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.5.1.1"></a><p></p>
<h4>Suppression</h4>
<p class="First"><span class="Italics">In adults</span>, 400 mg (=310 mg base) on exactly the same day of each week. <span class="Italics">In infants and children</span>, the weekly suppressive dosage is 5 mg, calculated as base, per kg of body weight, but should not exceed the adult dose regardless of weight.</p>
<p>If circumstances permit, suppressive therapy should begin two weeks prior to exposure. However, failing this, in adults an initial double (loading) dose of 800 mg (=620 mg base), or in children 10 mg base/kg may be taken in two divided doses, six hours apart. The suppressive therapy should be continued for eight weeks after leaving the endemic area.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.5.1.2"></a><p></p>
<h4>Treatment of the acute attack</h4>
<p class="First"><span class="Italics">In adults</span>, an initial dose of 800 mg (= 620 mg base) followed by 400 mg (=310 mg base) in six to eight hours and 400 mg (=310 mg base) on each of two consecutive days (total 2 g hydroxychloroquine sulfate or 1.55 g base). An alternative method, employing a single dose of 800 mg (=620 mg base), has also proved effective. </p>
<p>The dosage for adults may also be calculated on the basis of body weight; this method is preferred for infants and children. A total dose representing 25 mg of base per kg of body weight is administered in three days, as follows:</p>
<p>First dose: 10 mg base per kg (but not exceeding a single dose of 620 mg base).</p>
<p>Second dose: 5 mg base per kg (but not exceeding a single dose of 310 mg base) 6 hours after first dose.</p>
<p>Third dose: 5 mg base per kg 18 hours after second dose.</p>
<p>Fourth dose: 5 mg base per kg 24 hours after third dose.</p>
<p>For radical cure of <span class="Italics">vivax</span> and <span class="Italics">malariae</span> <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span> concomitant therapy with an 8-aminoquinoline compound is necessary.</p>
</div>
</div>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10"></a><p></p>
<h1><span class="product-label-link" type="condition" conceptid="255891" conceptname="Lupus erythematosus">LUPUS ERYTHEMATOSUS</span> AND <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">RHEUMATOID ARTHRITIS</span></h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.1"></a><p></p>
<h2>Indications</h2>
<p class="First">PLAQUENIL is useful in patients with the following disorders who have not responded satisfactorily to drugs with less potential for serious side effects: <span class="product-label-link" type="condition" conceptid="255891" conceptname="Lupus erythematosus">lupus erythematosus</span> (chronic discoid and systemic) and acute or chronic <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.2"></a><p></p>
<h2>Warnings</h2>
<p class="First">PHYSICIANS SHOULD COMPLETELY FAMILIARIZE THEMSELVES WITH THE COMPLETE CONTENTS OF THIS LEAFLET BEFORE PRESCRlBlNG PLAQUENIL.</p>
<p>Irreversible <span class="product-label-link" type="condition" conceptid="4188175" conceptname="Retinal damage">retinal damage</span> has been observed in some patients who had received long-term or high-dosage 4-aminoquinoline therapy for discoid and <span class="product-label-link" type="condition" conceptid="257628" conceptname="Systemic lupus erythematosus">systemic lupus erythematosus</span>, or <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span>.</p>
<p>When prolonged therapy with any Antimalarial compound is contemplated, initial (base line) and periodic (every three months) ophthalmologic examinations (including visual acuity, expert slit-lamp, funduscopic, and visual field tests) should be performed.</p>
<p>If there is any indication of abnormality in the visual acuity, visual field, color vision, or retinal macular areas (such as pigmentary changes, loss of foveal reflex), or any visual symptoms (such as light flashes and streaks) which are not fully explainable by difficulties of accommodation or corneal opacities, the drug should be discontinued immediately and the patient closely observed for possible progression. Retinal changes (and <span class="product-label-link" type="condition" conceptid="374034" conceptname="Visual disturbance">visual disturbances</span>) may progress even after cessation of therapy (see <a href="#Adverse">ADVERSE REACTIONS</a>).</p>
<p><span class="Bold">Retinal toxicity is largely dose-related.</span> The risk of <span class="product-label-link" type="condition" conceptid="4188175" conceptname="Retinal damage">retinal damages</span> is small with daily doses of up to 6.5 mg/kg body weight. Exceeding the recommended daily dose sharply increases the risk of retinal toxicity. This examination should be more frequent and adapted to the patient in the following situations:</p>
<dl>
<dt>-</dt>
<dd>daily dosage exceeding 6.5 mg/kg ideal body weight. Absolute body weight used as a guide to dosage, could result in an overdosage in the obese;</dd>
<dt>-</dt>
<dd><span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span>;</dd>
<dt>-</dt>
<dd>cumulative dose more than 200 g;</dd>
<dt>-</dt>
<dd>elderly;</dd>
<dt>-</dt>
<dd>impaired visual acuity.</dd>
</dl>
<p>All patients on long-term therapy with this preparation should be questioned and examined periodically, including the testing of knee and ankle reflexes, to detect any evidence of <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscular weakness</span>. If <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> occurs, discontinue the drug.</p>
<p>In the treatment of <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span>, if objective improvement (such as reduced <span class="product-label-link" type="condition" conceptid="4154927" conceptname="Joint swelling">joint swelling</span>, increased mobility) does not occur within six months, the drug should be discontinued. Safe use of the drug in the treatment of <span class="product-label-link" type="condition" conceptid="4079731" conceptname="Juvenile chronic arthritis">juvenile arthritis</span> has not been established.</p>
<p><span class="product-label-link" type="condition" conceptid="4322252" conceptname="Suicidal behavior">Suicidal behavior</span> has been reported in very rare cases in patients treated with hydroxychloroquine.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.3"></a><p></p>
<h2>Precautions</h2>
<p class="First">Dermatologic reactions to PLAQUENIL may occur and, therefore, proper care should be exercised when it is administered to any patient receiving a drug with a significant tendency to produce <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">dermatitis</span>.</p>
<p>The methods recommended for early diagnosis of "<span class="product-label-link" type="condition" conceptid="4208210" conceptname="Chloroquine retinopathy">chloroquine retinopathy</span>" consist of (1) funduscopic examination of the macula for fine pigmentary disturbances or loss of the foveal reflex and (2) examination of the central visual field with a small red test object for pericentral or paracentral <span class="product-label-link" type="condition" conceptid="377286" conceptname="Visual field defect">scotoma</span> or determination of retinal thresholds to red. Any unexplained visual symptoms, such as light flashes or streaks should also be regarded with suspicion as possible manifestations of <span class="product-label-link" type="condition" conceptid="376103" conceptname="Retinopathy">retinopathy</span>.</p>
<p>If serious toxic symptoms occur from overdosage or sensitivity, it has been suggested that ammonium chloride (8 g daily in divided doses for adults) be administered orally three or four days a week for several months after therapy has been stopped, as acidification of the urine increases renal excretion of the 4-aminoquinoline compounds by 20 to 90 percent. However, caution must be exercised in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span> and/or <span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">metabolic acidosis</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.4"></a><p></p>
<h2>Adverse Reactions</h2>
<p class="First">Not all of the following reactions have been observed with every 4-aminoquinoline compound during long-term therapy, but they have been reported with one or more and should be borne in mind when drugs of this class are administered. Adverse effects with different compounds vary in type and frequency. </p>
<p><span class="Bold Italics">CNS Reactions:</span> <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">Irritability</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, emotional changes, <span class="product-label-link" type="condition" conceptid="4009184" conceptname="Dream anxiety disorder">nightmares</span>, <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>, <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>, <span class="product-label-link" type="condition" conceptid="378165" conceptname="Nystagmus">nystagmus</span>, <span class="product-label-link" type="condition" conceptid="374366" conceptname="Sensorineural hearing loss">nerve deafness</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>, <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span> and <span class="product-label-link" type="condition" conceptid="4322252" conceptname="Suicidal behavior">suicidal behavior</span>.</p>
<p><span class="Bold Italics">Neuromuscular Reactions:</span> Skeletal muscle palsies or skeletal muscle <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> or <span class="product-label-link" type="condition" conceptid="4116861" conceptname="Neuromyopathy">neuromyopathy</span> leading to progressive <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> and <span class="product-label-link" type="condition" conceptid="4028206" conceptname="Atrophy">atrophy</span> of proximal muscle groups which may be associated with mild sensory changes, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> of tendon reflexes and abnormal nerve conduction.</p>
<p><span class="Bold Italics">Ocular Reactions:</span></p>
<ol class="BigAlpha">
<li>
<span class="Italics">Ciliary body</span>: Disturbance of accommodation with symptoms of <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>. This reaction is dose-related and reversible with cessation of therapy.</li>
<li>
<span class="Italics">Cornea</span>: Transient <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, punctate to lineal opacities, decreased corneal sensitivity. The corneal changes, with or without accompanying symptoms (<span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, halos around lights, <span class="product-label-link" type="condition" conceptid="4260194" conceptname="Photophobia">photophobia</span>), are fairly common, but reversible. <span class="product-label-link" type="condition" conceptid="4080669" conceptname="Keratic precipitates">Corneal deposits</span> may appear as early as three weeks following initiation of therapy. 							<p class="First">The incidence of corneal changes and visual side effects appears to be considerably lower with hydroxychloroquine than with chloroquine.</p>
</li>
<li>
<span class="Italics">Retina: Macula</span>: <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span>, <span class="product-label-link" type="condition" conceptid="4028206" conceptname="Atrophy">atrophy</span>, <span class="product-label-link" type="condition" conceptid="4083855" conceptname="Abnormal pigment">abnormal pigmentation</span> (mild pigment stippling to a "bull's-eye" appearance), loss of foveal reflex, increased macular recovery time following exposure to a bright light (photo-stress test), elevated retinal threshold to red light in macular, paramacular, and peripheral retinal areas. Cases of maculopathies and <span class="product-label-link" type="condition" conceptid="4083487" conceptname="Macular drusen">macular degeneration</span> have been reported and may be irreversible.<p class="First">Other fundus changes include optic disc <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pallor</span> and <span class="product-label-link" type="condition" conceptid="4028206" conceptname="Atrophy">atrophy</span>, attenuation of retinal arterioles, fine granular pigmentary disturbances in the peripheral retina and prominent choroidal patterns in advanced stage.</p>
</li>
<li>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="377286" conceptname="Visual field defect">Visual field defects</span></span>: Pericentral or paracentral <span class="product-label-link" type="condition" conceptid="377286" conceptname="Visual field defect">scotoma</span>, central <span class="product-label-link" type="condition" conceptid="377286" conceptname="Visual field defect">scotoma</span> with decreased visual acuity, rarely field constriction, abnormal color vision.<p class="First">The most common visual symptoms attributed to the <span class="product-label-link" type="condition" conceptid="376103" conceptname="Retinopathy">retinopathy</span> are: reading and seeing difficulties (words, letters, or parts of objects missing), <span class="product-label-link" type="condition" conceptid="4260194" conceptname="Photophobia">photophobia</span>, blurred distance vision, missing or <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">blacked out</span> areas in the central or peripheral visual field, light flashes and streaks.</p>
<p><span class="product-label-link" type="condition" conceptid="376103" conceptname="Retinopathy">Retinopathy</span> appears to be dose related and has occurred within several months (rarely) to several years of daily therapy; a small number of cases have been reported several years after antimalarial drug therapy was discontinued. It has not been noted during prolonged use of weekly doses of the 4-aminoquinoline compounds for suppression of <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span>.</p>
<p>Patients with retinal changes may have visual symptoms or may be asymptomatic (with or without visual field changes). Rarely scotomatous vision or field defects may occur without obvious retinal change.</p>
<p><span class="product-label-link" type="condition" conceptid="376103" conceptname="Retinopathy">Retinopathy</span> may progress even after the drug is discontinued. In a number of patients, early <span class="product-label-link" type="condition" conceptid="376103" conceptname="Retinopathy">retinopathy</span> (macular <span class="product-label-link" type="condition" conceptid="4083855" conceptname="Abnormal pigment">pigmentation</span> sometimes with central field defects) diminished or regressed completely after therapy was discontinued. If allowed to develop, there may be a risk of progression even after treatment withdrawal. Paracentral <span class="product-label-link" type="condition" conceptid="377286" conceptname="Visual field defect">scotoma</span> to red targets (sometimes called "premaculopathy") is indicative of early retinal dysfunction which is usually reversible with cessation of therapy.</p>
<p>A small number of cases of retinal changes have been reported as occurring in patients who received only hydroxychloroquine. These usually consisted of alteration in retinal <span class="product-label-link" type="condition" conceptid="4083855" conceptname="Abnormal pigment">pigmentation</span> which was detected on periodic ophthalmologic examination; <span class="product-label-link" type="condition" conceptid="377286" conceptname="Visual field defect">visual field defects</span> were also present in some instances. A case of delayed <span class="product-label-link" type="condition" conceptid="376103" conceptname="Retinopathy">retinopathy</span> has been reported with <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">loss of vision</span> starting one year after administration of hydroxychloroquine had been discontinued.</p>
</li>
</ol>
<p><span class="Bold Italics">Dermatologic Reactions: </span>Bleaching of hair, <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, skin and mucosal <span class="product-label-link" type="condition" conceptid="4083855" conceptname="Abnormal pigment">pigmentation</span>, photosentivity, and <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin eruptions</span> (urticarial, morbilliform, lichenoid, maculopapular, purpuric, <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>, <span class="product-label-link" type="condition" conceptid="4269878" conceptname="Erythema annulare centrifugum">erythema annulare centrifugum</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>, <span class="product-label-link" type="condition" conceptid="45773387" conceptname="Acute generalized exanthematous pustulosis">acute generalized exanthematous pustulosis</span>, and <span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">exfoliative dermatitis</span>).</p>
<p><span class="Bold Italics">Hematologic Reactions: </span>Various <span class="product-label-link" type="condition" conceptid="40528016" conceptname="Disorder of hematopoietic system">blood dyscrasias</span> such as <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span>, <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> (<span class="product-label-link" type="condition" conceptid="4126829" conceptname="Hemolysis">hemolysis</span> in individuals with glucose-6-phosphate dehydrogenase (G-6-PD) deficiency).</p>
<p><span class="Bold Italics">Gastrointestinal Reactions: </span><span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Anorexia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, and <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal cramps</span>. Isolated cases of abnormal liver function and <span class="product-label-link" type="condition" conceptid="4026032" conceptname="Acute hepatic failure">fulminant hepatic failure</span>.</p>
<p><span class="Bold Italics"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic reactions</span>:</span> <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">Urticaria</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> and <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span> have been reported.</p>
<p><span class="Bold Italics">Miscellaneous Reactions: </span><span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">Weight loss</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">lassitude</span>, exacerbation or precipitation of <span class="product-label-link" type="condition" conceptid="4305376" conceptname="Porphyria">porphyria</span> and nonlight-sensitive <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">psoriasis</span>.</p>
<p><span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">Cardiomyopathy</span> has been rarely reported with high daily dosages of hydroxychloroquine.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.5"></a><p></p>
<h2>Dosage and Administration</h2>
<p class="First">One tablet of hydroxychloroquine sulfate, 200 mg, is equivalent to 155 mg base.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.5.1"></a><p></p>
<h3></h3>
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="255891" conceptname="Lupus erythematosus">Lupus Erythematosus</span></span></p>
<p>Initially, the average <span class="Italics">adult</span> dose is 400 mg (=310 mg base) once or twice daily. This may be continued for several weeks or months, depending on the response of the patient. For prolonged maintenance therapy, a smaller dose, from 200 mg to 400 mg (=155 mg to 310 mg base) daily will frequently suffice. </p>
<p>The incidence of <span class="product-label-link" type="condition" conceptid="376103" conceptname="Retinopathy">retinopathy</span> has been reported to be higher when this maintenance dose is exceeded.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.5.2"></a><p></p>
<h3></h3>
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">Rheumatoid Arthritis</span></span></p>
<p>The compound is cumulative in action and will require several weeks to exert its beneficial therapeutic effects, whereas minor side effects may occur relatively early. Several months of therapy may be required before maximum effects can be obtained. If objective improvement (such as reduced <span class="product-label-link" type="condition" conceptid="4154927" conceptname="Joint swelling">joint swelling</span>, increased mobility) does not occur within six months, the drug should be discontinued. Safe use of the drug in the treatment of <span class="product-label-link" type="condition" conceptid="4253901" conceptname="Juvenile rheumatoid arthritis">juvenile rheumatoid arthritis</span> has not been established.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.5.2.1"></a><p></p>
<h4>Initial dosage</h4>
<p class="First">In <span class="Bold">adults</span>, from 400 mg to 600 mg (=310 mg to 465 mg base) daily, each dose to be taken with a meal or a glass of milk. In a small percentage of patients, troublesome side effects may require temporary reduction of the initial dosage. Later (usually from five to ten days), the dose may gradually be increased to the optimum response level, often without return of side effects.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.5.2.2"></a><p></p>
<h4>Maintenance dosage</h4>
<p class="First">When a good response is obtained (usually in four to twelve weeks), the dosage is reduced by 50 percent and continued at a usual maintenance level of 200 mg to 400 mg (=155 mg to 310 mg base) daily, each dose to be taken with a meal or a glass of milk. The incidence of <span class="product-label-link" type="condition" conceptid="376103" conceptname="Retinopathy">retinopathy</span> has been reported to be higher when this maintenance dose is exceeded. </p>
<p>Should a relapse occur after medication is withdrawn, therapy may be resumed or continued on an intermittent schedule if there are no ocular contraindications.</p>
<p><span class="Bold Italics">Corticosteroids and salicylates</span> may be used in conjunction with this compound, and they can generally be decreased gradually in dosage or eliminated after the drug has been used for several weeks. When gradual reduction of steroid dosage is indicated, it may be done by reducing every four to five days the dose of cortisone by no more than from 5 mg to 15 mg; of hydrocortisone from 5 mg to 10 mg; of prednisolone and prednisone from 1 mg to 2.5 mg; of methylprednisolone and triamcinolone from 1 mg to 2 mg; and of dexamethasone from 0.25 mg to 0.5 mg.</p>
</div>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-11"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">PLAQUENIL tablets are white, to off-white, film coated tablets imprinted "PLAQUENIL" on one face in black ink. Each tablet contains 200 mg hydroxychloroquine sulfate (equivalent to 155 mg base). Bottles of 100 tablets (NDC 0024-1562-10).</p>
<p>Dispense in a tight, light-resistant container as defined in the USP/NF.</p>
<p>Store at room temperature up to 30° C (86° F).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12"></a><p></p>
<h1></h1>
<p class="First">sanofi-aventis U.S. LLC<br>Bridgewater, NJ 08807<br>A SANOFI COMPANY</p>
<p>Revised April 2012</p>
<p>©2012 sanofi-aventis U.S. LLC</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-13"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 100 Tablet Bottle</h1>
<p class="First">NDC 0024-1562-10<br>NSN 6505-00-889-5790<br>P-647<br><span class="Bold">Rx only</span></p>
<p><span class="Bold">Plaquenil<span class="Sup">®</span></span><br><span class="Italics">hydroxychloroquine<br>sulfate, USP</span><br><span class="Bold">200 mg</span></p>
<p>100 tablets</p>
<p><span class="Bold">KEEP OUT OF THE REACH OF CHILDREN</span></p>
<p>Dispense in a tight, light-resistant container<br>as defined in the USP/NF.</p>
<p><span class="Bold">sanofi aventis</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 100 Tablet Bottle" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=1959d645-6b82-4f4d-b1f2-af644dec7c8f&amp;name=plaquenil-01.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>PLAQUENIL 		
					</strong><br><span class="contentTableReg">hydroxychloroquine sulfate tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0024-1562</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>hydroxychloroquine sulfate</strong> (hydroxychloroquine) </td>
<td class="formItem">hydroxychloroquine sulfate</td>
<td class="formItem">200 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Calcium Phosphate, Dibasic, Anhydrous</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Hypromelloses</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Magnesium Stearate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Polyethylene glycol 400</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Polysorbate 80</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Starch, Corn</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Titanium Dioxide</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">DOUBLE CIRCLE (peanut shaped) </td>
<td class="formLabel">Size</td>
<td class="formItem">12mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">PLAQUENIL</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0024-1562-10</td>
<td class="formItem">100  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA009768</td>
<td class="formItem">04/18/1955</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>sanofi-aventis U.S. LLC
							(824676584)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Sanofi Winthrop Industies</td>
<td class="formItem"></td>
<td class="formItem">763683216</td>
<td class="formItem">MANUFACTURE(0024-1562), ANALYSIS(0024-1562)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">sanofi-aventis U.S. LLC</td>
<td class="formItem"></td>
<td class="formItem">011330557</td>
<td class="formItem">LABEL(0024-1562), PACK(0024-1562)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 4/2013<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>c91c752e-ad6d-4b17-b1b5-2edc8a86856c</div>
<div>Set id: 1959d645-6b82-4f4d-b1f2-af644dec7c8f</div>
<div>Version: 8</div>
<div>Effective Time: 20130402</div>
</div>
</div> <div class="DistributorName">sanofi-aventis U.S. LLC</div></p>
</body></html>
